The novel tissue bioprosthesis demonstrated excellent surgical outcomes at 7 years, setting a benchmark for future prostheses.
Does aortic valve replacement with a novel Resilia tissue bioprosthesis provide safe and durable outcomes in adult patients requiring AVR?
The COMMENCE trial demonstrates that the Resilia tissue aortic valve bioprosthesis provides excellent durability with 99.3% freedom from structural valve deterioration and stable hemodynamics at 7 years.
We report the longest surgical AVR follow-up with novel tissue in an investigational device exemption trial utilizing an independent clinical events committee and an echocardiography core laboratory. This tissue demonstrates excellent outcomes through 7 years and is the benchmark for future surgical and transcatheter prostheses.
Beaver et al. (2023) studied this question. The novel tissue bioprosthesis demonstrated excellent surgical outcomes at 7 years, setting a benchmark for future prostheses.